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The Role of the POZ-ZF Transcription Factor Kaiso in Breast Cell Proliferation and Tumorigenesis

INTRODUCTION
The majority of fatal and invasive human tumors derive from epithelial origin. These tumors are characterized by their reduced intercellular adhesion, and increased mobility to secondary sites [1] . One complex that is essential for epithelial cell adhesion integrity and function is the E-cadherin-catenin complex. Malfunction of this complex has been implicated in ~50% of metastatic human carcinomas [1, 2] . E-cadherin is a transmembrane cell adhesion molecule that facilitates cell-cell adhesion via calcium-dependent homophilic interactions with other E-cadherin molecules on adjacent cells [3] . In the cytosol E-cadherin is anchored to the actin cytoskeleton via interactions with the catenin proteins (α-, β-, γ-, and p120 ctn ). β-catenin binds to the catenin binding domain (CBD) of E-cadherin and links E-cadherin to the actin cytoskeleton via α-catenin [4] . E-cadherin also interacts with p120 ctn (hereafter p120) at its juxtamembrane domain (JMD) and this increases cell-cell adhesion strength [5] . Although there is a correlation between tumor invasion, metastatic characteristics and the integrity of the E-cadherin/catenin complex, some tumors retain normal expression of Ecadherin and the classical catenins (β-and γ-). This implicates other catenins, for example p120, as important factors in tumor progression. In an effort to further decipher p120 function a yeast-two hybrid screen using p120 as bait was performed. This identified the POZ-ZF protein Kaiso as a p120-specific binding partner [6] . Kaiso is a dual specificity transcription factor that can bind to both a sequence specific Kaiso binding site (KBS) TCCTGCNA and methylated CpG residues [7, 8] . Studies from our lab here found that Kaiso is misexpressed in ~40% of human breast tumors. This is consistent with the fact that POZ-ZF transcription factors have roles in cancer as either oncoproteins or tumor suppressors [6, 9, 10] .
Several lines of evidence from our lab and others implicate Kaiso and p120 as modulators of Wnt/β-catenin signaling whose malfunction is implicated in several human cancers. We found that a subset of Wnt/β-catenin target genes, including cyclin D1, possessed two or more copies of the sequence specific KBS. This finding raises the possibility that Kaiso was a potential regulator of cyclin D1, a key cell cycle protein that is aberrantly expressed in human breast cancers [11] [12] [13] . The research performed by myself and the previous P.I. of this award, Ms. Abena Otchere revealed that Kaiso binds the cyclin D1 promoter region in vitro and in vivo and represses the cyclin D1 promoter. We also found whereas p120 activates a minimal cyclin D1-promoter that Kaiso inhibits β-catenin-mediated activation of the minimal cyclin D1-promoter. Furthermore, we found that overexpression or depletion of Kaiso in the MCF7 human breast cancer cell line resulted in a positive correlation of Cyclin D1 levels. These initial findings suggested that Kaiso and p120 may be involved in a signaling pathway, where Kaiso regulates genes involved in tumorigenesis and its binding partner p120 serves to modulate its function. These findings support our hypothesis that Kaiso plays a role in breast cell proliferation and tumorigenesis via its regulation of cyclin D1 expression.
Ms. Abena Otchere, the original P.I of this grant, graduated and entered medical school approximately one year after the award was granted to her. (Figure 1, Appendix) . After obtaining human breast tissue for antibody optimization we found that Kaiso staining was not seen. Further optimization using higher antibody concentrations is currently underway. Analysis of 650 annotated breast tumor tissue samples will then be performed in collaboration with Dr. David Rimm at the Yale University Cancer Center using automated quantitative analysis (AQUA), an objective method of scoring developed by Dr. Rimm's laboratory. Aim 1.2: Generate a Kaiso-overexpression model system. In order to create a human breast cancer Kaisooverexpression cell line, MCF7 breast tumor cells were transfected with the pcDNA3 human Kaiso expression construct. The pcDNA3 plasmid contains a neomycin resistance gene which is used as a selectable marker for stable cell line creation (Invitrogen). I have successfully created this Kaiso overexpression cell line after screening many putative clones (Figure 2, Appendix) . These cell lines along with Kaiso depleted cell lines, were used in experiments to determine the effect of Kaiso misexpression on Cyclin D1 protein levels (Specific Aim 2.2, below). Kaiso-overexpressing cell lines will also be used to complete Specific Aim 1.3 which is to determine the effects of Kaiso misexpression on breast cell growth and transformation. A total of three potential Kaiso binding sites were identified within the cyclin D1 promoter. They are located at -1118, +24 and +1050 with respect to the transcriptional start site (Figure 3 ). 30 bp oligonucleotides, which span each of these KBS sites, were created and Kaiso binding to these determined using electrophoretic mobility shift assays (EMSA). We found that purified Kaiso fusion constructs bound to the -1118 KBS oligonucleotide (Figure 4) . Furthermore, when point mutations were introduced in this KBS site, binding was abolished (Figure 4) . Unlike the -1118 KBS derived oligonucleotide, the +24 and +1050 KBS derived oligonucleotides did not bind to Kaiso fusion constructs in these experiments ( Figure 5 ). As Kaiso has been shown to have dual DNA binding specificity the possibility existed that Kaiso could bind to these regions in a methylation-dependent manner [7] . To test this possibility the +24 and +1050 KBS derived oligonucleotides were methylated in vitro and tested for Kaiso binding in EMSAs. Kaiso fusion proteins bound to the methylated +24 KBS derived oligonucleotides but not to the +1050 KBS derived oligonucleotides ( Figure 6 ). These data suggest that Kaiso may regulate the cyclin D1 promoter through two mechanisms, via a KBS-specific site at the -1118 KBS site and a methylation-specific manner in the region containing the +24 KBS sequence. Kaiso binding to these two regions of the cyclin D1 promoter was detected in vivo through chromatin immunoprecipitation assays (ChIP) (Figure 7 ).
Since Kaiso binds methylated CpG dinucleotides this led us to search the cyclin D1 promoter region for CpG islands and we identified 10 potential CpG-dinucleotide pairs (i.e. CpGCpG) that may be recognized and bound by Kaiso (Figure 3 ). Eight oligonucleotides were created to span each of these sequences. These oligonucleotides were tested for their ability to bind Kaiso in both a methylation-dependent and independent manner in EMSA experiments. Kaiso bound all eight of the methylated but not unmethylated oligonucleotides (Figure 8 ). It was shown that although Kaiso bound all of the methylated CpGCpG sequences, it did so with different affinities. To determine the relative affinity of Kaiso binding to the eight CpG-site oligonucleotides, an EMSA using all eight probes and GST-hKaiso ZF construct was performed. Kaiso bound CpG5 and CpG8 oligonucleotides with higher affinity than any other CpG site, suggesting that these sites were more physiologically relevant (Figure 9 ). These two strong binding sites (CpG5 & CpG8) were further tested for binding to the full-length wild-type Kaiso and Kaiso-zinc finger point mutants. The two strongest binding CpG sites bound to the full-length Kaiso-GST fusion protein (Figure 10 ) while the two weakest sites (CpG3 and CpG6) did not bind (data not shown). Cold-competition assays of the high affinity CpG5 and CpG8 sites revealed that excess cold probe outcompeted binding to these regions (Figure 11 ). This finding underscores the specificity of Kaiso-CpG binding.
To determine if Kaiso regulates cyclin D1 expression, promoter reporter assays were performed in HeLa cells using a minimal cyclin D1 promoter-luciferase reporter construct. These experiments clearly demonstrated that human Kaiso is a dose-dependent transcriptional repressor of the cyclin D1 promoter (Figure 12 ). This was the first experimental evidence that Kaiso may indeed regulate cyclin D1 transcript expression. Sitedirected mutagenesis was used to create point-mutations in the two sequence-specific KBSs (-1118 and +24) located within the cyclin D1 promoter fragment of the 1748CD1 construct. Unexpectedly, Kaiso was still able to repress luciferase expression under the control of the mutant KBS cyclin D1 promoter constructs ( Figure  13 ). Since Kaiso is a bi-modal transcription repressor that also recognizes and binds methyl-CpG, we postulated that Kaiso's effects on the cyclin D1 promoter may be due to its association with methylated CpG sites in the cyclin D1 promoter [7] , in addition to the sequence-specific KBS.
To test this hypothesis we tested the effects of Kaiso on the 962CD1 luciferase reporter construct, which lacks the -1118 KBS and contains all putative CpG sites were analyzed. Kaiso repressed luciferase expression 2-fold (Figure 14) , suggesting that indeed Kaiso's binding to methyl-CpG DNA sites contributes to its transcriptional repression of cyclin D1. To further test the effect of Kaiso-mediated methylation-specific repression of the cyclin D1 promoter, we performed a series of promoter-reporter luciferase assays were performed following in vitro methylation of the 1748CD1 cyclin D1 partial promoter-reporter construct. We found that when methylated, the 1748CD1 construct was fully repressed both in the presence and absence of ectopic Kaiso (Figure 15 ). This raised the possibility that endogenous Kaiso was repressing the 1748CD1 promoter.
Aim 2.2: Examine the effects of Kaiso misexpression on cyclin D1 expression.
To determine the effects of Kaiso depletion on Cyclin D1 protein levels, an siRNA-mediated Kaiso knockdown stable MCF7 cell line was used. Cells were either serum starved or serum stimulated 24 hours prior to harvesting, and Kaiso and Cyclin D1 protein levels were ascertained by Western blot. Depletion of Kaiso resulted in a decrease in Cyclin D1 protein levels (Figure 16 ). These data indicate that Kaiso may positively regulate Cyclin D1 in this cell line.
In order to further confirm the results found in the depletion cell lines, cell cycle synchronization and restimulation was performed on both the Kaiso overexpression and depletion cell lines. Cells were grown to approximately 50% confluency prior to serum starvation for 24 hours. After 24 hours of serum starvation for cell cycle synchronization a 12 hour time course of serum stimulation was performed. The cells were harvested and tested for Cyclin D1 and Kaiso protein levels. Consistent with unsynchronized Kaiso-depleted cell lines, knockdown of Kaiso resulted in a decrease in Cyclin D1 expression (Figure 17) . Furthermore, this trend was seen in all cell cycle stages. Interestingly, Kaiso levels seemed to decrease as the cell cycle progressed, being highest during serum starvation and decreasing as the cells were serum stimulated. In the MCF7 overexpression cell lines it was also seen that Kaiso overexpression resulted in an increase in Cyclin D1 expression. In summary, both the Kaiso overexpression and depletion MCF7 cell lines showed that Kaiso and Cyclin D1 exhibit a positive correlation with respect to protein expression levels. These data were unexpected since the luciferase-reporter assays performed in HeLa cells suggested that Kaiso represses the cyclin D1 promoter. The possibility exists that Kaiso's dual mechanism of DNA binding also represents different transcriptional regulatory functions. As methylated DNA binding is associated with DNA repression, this may be the mechanism of regulation seen in HeLa cells. As the cyclin D1 promoter in MCF7 cells is hypomethylated [14] this would suggest that Kaiso's regulation of cyclin D1 in this cell line is independent of methylation and is sequence specific. This would be consistent with the fact that Kaiso is a transcription factor which along with transcriptional repression functions has also been shown to transcriptionally activate the neuromuscular gene rapsyn [15] .
Outcome:
1. Kaiso binds the cyclin D1 promoter in vitro and in vivo. To analyze the effects of p120 overexpression alone on the cyclin D1 promoter, promoter-luciferase assays were performed. p120 activated cyclin D1 expression (Figure 18 ), however repeated experiments could not definitely conclude that p120 relieves Kaiso-mediated repression of the promoter. Together these results suggest that p120 activation of the cyclin D1 promoter may be independent of its interaction with Kaiso, and that the p120 transcription activation effects may be due to other intracellular signaling pathways that p120 is involved in, e.g. p120 regulation of the RhoA family of GTPases [16] .
Kaiso regulates
Aim 3.2: Determine if p120
ctn /Kaiso antagonize or synergize with β-catenin/TCF regulation of cyclin D1. Since the p120/Kaiso interaction is reminiscent of the β-catenin/TCF interaction, and β-catenin/TCF are well-documented transcriptional regulators of cyclin D1, I investigated whether Kaiso and p120 synergize or antagonize with β-catenin/TCF regulation of cyclin D1 using luciferase assays. Kaiso inhibited β-cateninmediated activation of the cyclin D1 promoter while p120 enhanced this activation (Figure 19 ). This exciting finding corroborates previous studies by us and our collaborator (Dr. Pierre McCrea) that Kaiso and p120 are indirect regulators of canonical Wnt signaling [17, 18] .
To determine the effect of p120 on Kaiso's ability to inhibit β-catenin-mediated activation of the cyclin D1 promoter, I performed promoter-luciferase assays using the 1748CD1 cyclin D1 promoter-reporter plasmid, Kaiso, p120 and β-catenin overexpression vectors in HeLa cells. Due to inefficient transfection and overexpression (as determined by western blot) of the β-catenin overexpression plasmid the results obtained were inconclusive and need to be repeated. I am currently in the process of optimizing transfection efficiency of the β-catenin overexpression plasmid and will repeat the luciferase assay.
Outcome:
1. p120 activates the cyclin D1 promoter.
Kaiso inhibits β-catenin-mediated activation of cyclin D1.
3. p120 enhances β-catenin-mediated activation of cyclin D1. 
Development of cell lines:
• Creation of a breast tumor, Kaiso overexpressing stable cell line.
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CONCLUSIONS
Our tenure of this award has been very rewarding and productive. Our findings have indicated that Kaiso is a transcriptional regulator of the cyclin D1 gene, potentially both activating and repressing cyclin D1 expression depending on the cellular environment. We have also shown that the cyclin D1 gene is potentially regulated by Kaiso through two different mechanisms; both sequence-specific and methylation-dependent manners. This would make cyclin D1 a unique Kaiso target gene which differs mechanistically from Kaiso's other target genes such as matrilysin or Wnt11 [18, 19] . Due to time constraints and technical difficulties we were unable to complete a few subaims namely analysis and comparison of Kaiso and Cyclin D1 protein levels in breast tumor tissue samples (Aim 1). I am optimistic that optimization of Kaiso antibodies for human tissue in immunohistochemistry will be accomplished in the next month. Assessment of Kaiso misexpression effects on cell proliferation and transformation (Aim 1) is another aspect that remains to be completed but we now have the reagents necessary to complete this aim in the near future. Our continued investigations will analyze the role that Kaiso plays directly in the cell biology of breast tumorigenesis. Our findings will contribute to understanding the role of Kaiso in breast tumorigenesis and may contribute to the future development of novel diagnostic, prognostic, and therapeutic tools in the fight against breast cancer. The Kaiso overexpression plasmid, pcDNA3-hKaiso, which contains a neomycin resistance gene, was transfected into MCF7 cells. Cells were selected in G418 drug for 3 weeks and clones were isolated and tested for Kaiso overexpression. A number of positive clones were identified, with clone #27 and #28 having the highest expression of Kaiso. These cell lines were subsequently used in a number of experiments to assess the effects of Kaiso misexpression on Cyclin D1 expression. β-tubulin serves as a loading control. 
+1050 KBS -1118 KBS +24 KBS
Intron 1
Predicted CpG islands CpG1-Unmethylated CpG1-Methylated 
+24KBS CpG5
+ + ----+ + + + ----+ + + + CpG5 CpG8 CpG8
Figure 11: Kaiso specifically binds to the CpG5 and CpG8 regions when methylated. cyclin D1-promoter-derived CpG5 and CpG8 oligonucleotides were methylated in vitro, radiolabelled and incubated with GST-Kaiso proteins. Cold probe was added to the reactions at 25X and 50X excess labelled probe. Methylated cold probe was able to outcompete the binding of the GST-Kaiso ZF and full-length protein.
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